JPRN-UMIN000000968已完成未知
Treatment for CD20-positive central nervus system lymphoma with autologous serum and rituximab into the ventricle - CNS lymphoma treatment with auto-serum and rituximab into the ventricle
Division of Hematology, University of Tsukuba0 个研究点目标入组 5 人开始时间: 2008年1月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Poor general status (ECOG Performance status 3 or 4). Inablity in understanding of the therapy even due to the primary disease. Lesions outside of central nervas system which are uncontroled or less than three months from shrinking.
研究者
相似试验
进行中（未招募）
1 期
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaMedDRA version: 8.1Level: PTClassification code 10007953Term: Central nervous system lymphomaEUCTR2006-004772-12-DKordic Lymphoma Group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with rituximab, HD-MTX, HD Ara-C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide,and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide - NLG PCNSEUCTR2006-004772-12-FIordic lymphoma group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaEUCTR2006-004772-12-SEordic Lymphoma Group70
已完成
2 期
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell LymphomaDiffuse large B-cell lymphomaC83.3C82.4C85.1Follicular lymphoma grade IIIbB-cell lymphoma, unspecifiedDRKS00009416niversitätsmedizin der Johannes Gutenberg-Universität Mainz70
已完成
不适用
Anti-CD20 therapy for the treatment of chronic Graft Versus Host DiseaseChronic Graft Versus Host Disease (cGVHD)Injury, Occupational Diseases, PoisoningFailure and rejection of transplanted organsISRCTN43525354niversity Medical Center Utrecht (UMCU) (The Netherlands)30